Dr. Reddy’s Laboratories along with its subsidiaries has terminated the license granted to Armis Biopharma (formerly known as CHO Bioscience) for its investigational antibacterial product, DFA-02, for the prophylaxis of surgical site infections (SSIs). As a result of the termination, the company has regained worldwide rights to DFA-02, and is currently evaluating its options to take the program forward.
DFA-02 is a combination, broad spectrum antibacterial in situ gel which is being investigated for the prophylaxis of SSIs as an adjunct to conventional preoperative antibiotic prophylaxis. DFA-02 has been studied in several phase 1 and 2 clinical studies, and has demonstrated clinical efficacy in several key segments of patients who were at high risk for SSIs.
Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
